ALKternate: A Proof of Concept Study in ALK-Rearranged NSCLC Alternating Lorlatinib With Crizotinib After Disease Progression

被引：0
|
作者：
Itchins, M. [1 ]
Liang, S. [1 ]
Brown, C. [2 ]
Solomon, B. [3 ]
Pavlakis, N. [1 ]
机构：
[1] Royal North Shore Hosp, Med Oncol, St Leonards, NSW, Australia
[2] Univ Sydney, Nhmrc Clin Trials Ctr, Camperdown, NSW, Australia
[3] Peter Maccallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
Drug resistance; ALK; Clinical trial;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P47.12
引用
收藏
页码：S1101 / S1102
页数：2
相关论文
共 50 条
  • [41] Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC
    Yun, Karen M.
    Bazhenova, Lyudmila A.
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 843 - 850
  • [42] Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset
    Kiura, Katsuyuki
    Imamura, Fumio
    Kagamu, Hiroshi
    Matsumoto, Shingo
    Hida, Toyoaki
    Nakagawa, Kazuhiko
    Satouchi, Miyako
    Okamoto, Isamu
    Takenoyama, Mitsuhiro
    Fujisaka, Yasuhito
    Kurata, Takayasu
    Ito, Masayuki
    Tokushige, Kota
    Hatano, Ben
    Nishio, Makoto
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (04) : 367 - 375
  • [43] Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study.
    Nakagawa, Kazuhiko
    Hida, Toyoaki
    Seto, Takashi
    Satouchi, Miyako
    Nishio, Makoto
    Hotta, Katsuyuki
    Murakami, Haruyasu
    Ohe, Yuichiro
    Takeda, Koji
    Tatsuno, Masahiro
    Yoshikawa, Naoki
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Identification and monitoring of a high-level MET amplification in CTCs and cfTNA in an ALK-rearranged NSCLC patient treated with crizotinib, alectinib and ceritinib
    Berger, L. A.
    Velthaus, J. L.
    Janning, M.
    Schatz, S.
    Falk, M.
    Iglauer, P.
    Simon, R.
    Cao, R.
    Bramlett, K.
    Buson, G.
    Petrini, E.
    Forcato, C.
    Tiemann, M.
    Sauter, G.
    Bokemeyer, C.
    Reck, M.
    Riethdorf, S.
    Pantel, K.
    Wikman, H.
    Loges, S.
    CLINICAL & EXPERIMENTAL METASTASIS, 2018, 35 (03) : 183 - 183
  • [45] Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
    Angeles, Arlou Kristina
    Christopoulos, Petros
    Yuan, Zhao
    Bauer, Simone
    Janke, Florian
    Ogrodnik, Simon John
    Reck, Martin
    Schlesner, Matthias
    Meister, Michael
    Schneider, Marc A.
    Dietz, Steffen
    Stenzinger, Albrecht
    Thomas, Michael
    Sultmann, Holger
    NPJ PRECISION ONCOLOGY, 2021, 5 (01)
  • [46] Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report
    Flávia Amaral Duarte
    Leonardo Brand Rodrigues
    Flávia Rocha Paes
    Paulo Henrique Costa Diniz
    Helena Flávia Cuba de Almada Lima
    BMC Pulmonary Medicine, 21
  • [47] Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis
    Arlou Kristina Angeles
    Petros Christopoulos
    Zhao Yuan
    Simone Bauer
    Florian Janke
    Simon John Ogrodnik
    Martin Reck
    Matthias Schlesner
    Michael Meister
    Marc A. Schneider
    Steffen Dietz
    Albrecht Stenzinger
    Michael Thomas
    Holger Sültmann
    npj Precision Oncology, 5
  • [48] Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report
    Duarte, Flavia Amaral
    Rodrigues, Leonardo Brand
    Paes, Flavia Rocha
    Costa Diniz, Paulo Henrique
    Cuba de Almada Lima, Helena Flavia
    BMC PULMONARY MEDICINE, 2021, 21 (01)
  • [49] Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease
    Domenech, Marta
    Jove, Maria
    Aso, Samantha
    Marin, Mar
    Nadal, Ernest
    LUNG CANCER, 2018, 119 : 99 - 102
  • [50] Alectinib provides a new option for ALK-positive NSCLC patients after progression on crizotinib
    Abraham, Jame
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2016, 14 (06): : 241 - 243
12345